Safety and immunogenicity of a paediatric presentation of an influenza vaccine

Archives of Disease in Childhood

Volumn 83, Issue 6, 2000, Pages 488-491

  Gonzalez, M ^a   Pirez, M C ^a   Ward, E ^a   Dibarboure, H ^b   Garcia, A ^c   Picolet, H ^c  

^a Centro Materno Infantil Maciel   (Uruguay)

^b Aventis Pharma   (Uruguay)

^c SANOFI PASTEUR   (France)

Author keywords

Immunogenicity; Influenza; Influenza vaccine; Safety

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PAPULE; PRESCHOOL CHILD; PRIORITY JOURNAL; VACCINATION;

ANTIBODIES, VIRAL; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; VACCINATION; VACCINES, INACTIVATED;

EID: 0033635148     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.83.6.488     Document Type: Article

References (23)

1. Prevention and control of influenza
2. Influenza immunization for children with bronchopulmonary dysplasia in Poland
3. Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukemia
4. Influenza in patients with human immunodeficiency infection
5. The effect of influenza on hospitalizations, outpatient visits and courses of antibiotics in children
6. Influenza and the rates of hospitalization for respiratory disease among infants and young children
7. Acute otitis media and respiratory virus infections
8. Consideration of the risk of influenza in children and indications for prophylaxis
9. Influenza immunization: Clinical studies with ether-split subunit vaccines
10. Comparison of a new triton-X-100 and twenn-ether-treated split vaccines in children
11. A Triton-X-100-split influenza vaccine is safe and fulfills the European Agency for Evaluation of Medicinal Products recommendations for immunogenicity in children, adults and the elderly
12. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine
13. Safety and immunogenicity of an inactivated triton split influenza vaccine in different age groups
14. An optimization model for influenza A epidemics
15. Middle ear disease and the practice of pediatrics: Burden during the first five years of life
16. Influenza vaccination in the prevention of acute otitis media in children
17. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month old children in day care
18. Immunization of elderly volunteers with the 1988-1989 inactive whole influenza vaccine: Assessment of antibody responses by haemagglutination inhibition and single radial haemolysis tests
19. Influenza immunization in children with neoplastic diseases
20. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccine in high-risk children
21. The influence human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines